Recombinant Factor VIIa to Control Excessive Bleeding Following Surgery for Congenital Heart Disease in Pediatric Patients

Abstract

The purpose of this article is to evaluate the efficacy of recombinant factor VII (rFVIIa) in the treatment of bleeding following cardiac surgery in a pediatric population. The study included a case series of postcardiac surgical patients with chest tube output of= 4 mL/kg/h for the initial 3 postoperative hours who received rFVIIa. Chest tube output for the 3 hours before and the 3 hours after rFVIIa was compared using a pairedt test. In addition, chest tube output for the initial 3 postoperative hours and the 3 hours following rFVIIa was compared to 8 control patients who did not require rFVIIa. Recombinant factor VIIa was administered to 9 children (age = 9 ± 4 years) following repair of tetralogy of Fallot (6), closure of ventricular septal defect (1), closure of sinus venosus atrial septal defect (1), and mitral valve repair (1). Chest tube output for the initial 3 postoperative hours prior to the administration of rFVIIa was 5.8 ± 2.8 mL/kg/h and decreased to 2.0 ± 1.3 mL/kg/h for the 3 hours following the administration of rFVIIa (P= .002). In the patients that did not receive rFVIIa, chest tube output for the first 3 postoperative hours was 1.6 ± 0.9 mL/kg/h and 1.2 ± 0.6 mL/kg/h for the next 3 hours (P= nonsignificant when compared to chest tube output for the 3 hours following rFVIIa in patients who received rFVIIa). No adverse effects were noted. Recombinant factor VIIa decreased chest tubing bleeding following cardiac surgery in children. Given its potential therapeutic impact, rFVIIa warrants further investigation in the pediatric cardiac population.

Keywords

recombinant factor VIIa chest tubing bleeding congenital heart disease pediatric cardiac patients

Get full access to this article

View all access options for this article.

References

1. Tempe DK , Virmani S. Coagulation abnormalities in patients with cyanotic congenital heart disease. J Cardiothorac Vasc Anes. 2002;16:752-765.

2. Cote CJ , Drop LJ , Hoaglin DC , Daniels AL , Young ET . Ionized hypocalcemia after fresh frozen plasma administration to thermally injured children. Anesth Analg. 1988;67:152-160.

3. Hedner U , Schulman S , Alberta KA , et al. Successful use of rFVIIa in a patient with severe hemophilia A subjected to synovectomy. Lancet. 1988;342:1193-1193.

4. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost. 2000;26:363-366.

5. Chuansumrit A , Chantarojanasiri T , Isarangkura P , et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S101-S105.

6. Chuansumrit A , Treepongkaruna S , Phuapradit P , et al. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost.2001;85:748-749.

7. Tobias JD . Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology. 2003;96:1522-1525.

8. Tobias JD , Groeper K , Berkenbosch JW . Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J. 2003;96:12-16.

9. Morenski JD , Tobias JD , Jimenez DF . Recombinant activated factor VII for cerebral injury induced coagulopathy in pediatric patients. J Neurosurg. 2003;98:611-616.

10.

10. Al Douri M , Shafi T , Al Khudairi D , et al. Effect of the administration of recombinant activated factor VII (rFVIIa; Novo Seven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis.2000;11(suppl):S121-127.

11.

11. Tobias JD , Berkenbosch JW , Russo P. Recombinant factor VIIa to treat bleeding following cardiac surgery in an infant. Pediatr Crit Care Med.2003;4:49-51.

12.

12. von Heymann C , Hotz H , Konertz W , Kox WJ , Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothor Vasc Anesth.2002;16:615-616.

13.

13. Hendriks HGD , van der Maaten MAA , de Wolf J , Waterbolk TW , Slooff MJH , van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg. 2001;93:287-289.

14.

14. Tanaka KA , Waly AA , Cooper WA , Levy JH . Treatment of excessive bleeding in Jehovah’s witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology. 2003;98:1513-1515.

15.

15. Potapov EV , Pasic M , Bauer M , Hetzer R. Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg. 2002;74:2182-2183.

16.

16. Zietkiewicz M , Garlicki M , Domagala J , et al. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thor Cardiovasc Surg. 2002;123:384-385.

17.

17. Poon MC , Demers C , Jobin F , Wu JWY . Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann’s thrombasthenia. Blood. 1999;94:3951-3953.

18.

18. Kristensen J , Killander A , Hippe E , et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(suppl 1):159-164.

19.

19. Carson JL , Altman DG , Duff A , et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion. 1999;39:694-700.

20.

20. Taylor RW , Manganaro L , O’Brien J , et al. Impact of allogeneic packed red blood cell transfusion on nosocomial infectious rates in critically ill patients. Crit Care Med. 2002;30:2249-2256.